Arch Oncology is a clinical-stage immuno-oncology company focused on the discovery and development of antibody therapies for the treatment of patients with cancer. The Company's lead product candidate AO-176 is in Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, Arch Oncology is advancing pipeline programs, including anti-signal regulatory protein (SIRP) antibodies.
|HQ||Brisbane, CA, US||Map|
|Employees (est.) (Sept 2021)||27||(-6%)|
Arch Oncology total Funding
Arch Oncology latest funding size
Time since last funding
|5 months ago|
Arch Oncology investors
|Roche Venture Fund, RiverVest, Adage Capital Management, 3x5 Special Opportunity Fund, Eventide Asset Management, Cowen Healthcare Investments, RiverVest Venture Partners, Lightchain, 3×5 Partners, Point72 Asset Management, Avego Healthcare Capital, FMB Research, Broadfin Holdings|
When was Arch Oncology founded?
Arch Oncology was founded in 2006.
Who are Arch Oncology key executives?
Arch Oncology's key executives are John McKearn, Daniel Pereira and Arun Kashyap.
How many employees does Arch Oncology have?
Arch Oncology has 28 employees.
Who are Arch Oncology competitors?
Competitors of Arch Oncology include CG Oncology, Priothera and Tollys.
Where is Arch Oncology headquarters?
Arch Oncology headquarters is located at 2000 Sierra Point Pkwy #700Brisbane, Brisbane.
Where are Arch Oncology offices?
Arch Oncology has offices in Brisbane and St. Louis.
How many offices does Arch Oncology have?
Arch Oncology has 2 offices.
Receive alerts for 300+ data fields across thousands of companies